Compare Pfizer Inc (PFE) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

SQQQ trades at $42.68, down 0.26% on the day, with a bullish technical signal from moving averages but neutral oscillators. As a leveraged inverse ETF, it aims to deliver -3x the daily return of the Nasdaq-100, making it a tactical tool for hedging or short-term bearish bets rather than a long-term investment. Recent news highlights its role in protecting QQQ holdings but warns of severe erosion from daily resets.

The outlook for SQQQ is highly speculative, suited only for experienced traders timing tech sector declines. Key risks include volatility decay and reliance on accurate market timing, with long-term performance showing near-total loss since inception. It offers no fundamental value like earnings or dividends, serving purely as a hedging instrument.